Insulin producer Indar plans to build a new workshop to produce active pharmaceutical ingredients (API) by the middle of 2019, Indar Board Chairperson Liubov Vyshnevska said at a press conference at Interfax-Ukraine on Thursday.
“We have switched to the design stage of construction of a new workshop for production of API. By the middle of 2019 we will complete this issue and will have new capacities with a significant increase in production of API, as well as production of our own three analogues of insulin,” she said.
Vyshnevska said that at present, the scientific division of the company has completed development of three strains of insulin analogues.
Commenting on the results of the company’s work in 2017, she said that Indar brought two sugar-reducing drugs to the market in tablets, began delivering its drugs to Mozambique and Cote d’Ivoire, and also won 100% of insulin shipments to Moldova and Tajikistan.
Indar was created under a resolution of the Cabinet of Ministers in 1997 under the aegis of Kyiv meat processing plant. The producer is on the list of state-owned companies of strategic importance for the economy and security of the state.
Indar is a member of the Association Manufacturers of Medications of Ukraine.
